(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 November 2001 (01.11.2001)

PCT

(10) International Publication Number
WO 01/81919 A2

(51) International Patent Classification[7]: G01N 33/50

(21) International Application Number: PCT/US01/13378

(22) International Filing Date: 26 April 2001 (26.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/559,779 27 April 2000 (27.04.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/559,779 (CIP)
Filed on 27 April 2000 (27.04.2000)

(71) Applicant *(for all designated States except US)*: **BIONEBRASKA, INC.** [US/US]; 3820 N.W. 46th Street, Lincoln, NE 68524 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NAUCK, Michael, A.** [DE/DE]; Am Hang 4, 37431 Bad Lauterberg im Harz (DE). **MEIER, Juris, J.** [DE/DE]; Egidestrasse 23, 44852 Bochum (DE). **HUECKING, Katrin** [DE/DE]; Schuetzenstrasse 36, 58640 Iserlohn (DE).


(74) Agents: **BURROUS, Beth, A.** et al.; Foley & Lardner, 3000 K. Street, NW, Washington, DC 20007-5109 (US).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: GASTRIC INHIBITORY POLYPEPTIDE DIAGNOSTIC TEST FOR DETECTING SUSCEPTIBILITY TO TYPE-2 DIABETES, IMPAIRED GLUCOSE TOLERANCE, OR IMPAIRED FASTING GLUCOSE



(57) Abstract: Methods and kits for determining whether an individual is susceptible to developing impaired glucose tolerance (IGT), impaired fasting glucose (IFG), or Type-2 diabetes are described. Such methods include administering GIP or GIP variant and nutrient to an individual, measuring the response of the individual and determining whether the individual is susceptible to developing IGT, Type-2 diabetes, or IFG.

WO 01/81919 A2

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.